Zacks: Brokerages Anticipate Maximus, Inc. (MMS) Will Announce Earnings of $0.77 Per Share
Analysts expect that Maximus, Inc. (NYSE:MMS) will announce $0.77 earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have provided estimates for Maximus’ earnings, with the highest EPS estimate coming in at $0.78 and the lowest estimate coming in at $0.75. Maximus also posted earnings per share of $0.77 in the same quarter last year. The company is scheduled to issue its next quarterly earnings report on Thursday, November 9th.
According to Zacks, analysts expect that Maximus will report full-year earnings of $3.13 per share for the current year, with EPS estimates ranging from $3.12 to $3.14. For the next financial year, analysts expect that the business will post earnings of $3.22 per share, with EPS estimates ranging from $3.15 to $3.30. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Maximus.
Maximus (NYSE:MMS) last released its quarterly earnings data on Thursday, August 3rd. The health services provider reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.03. The firm had revenue of $600.40 million during the quarter, compared to analysts’ expectations of $614.12 million. Maximus had a return on equity of 25.08% and a net margin of 8.43%. Maximus’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.79 earnings per share.
Several brokerages have recently weighed in on MMS. Robert W. Baird began coverage on Maximus in a report on Sunday, September 3rd. They issued a “neutral” rating for the company. Canaccord Genuity lowered Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective for the company. in a report on Tuesday, July 4th. BidaskClub lowered Maximus from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Zacks Investment Research lowered Maximus from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Finally, Maxim Group set a $66.00 price objective on Maximus and gave the company a “hold” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. Maximus has an average rating of “Hold” and a consensus price target of $63.14.
In other news, General Counsel David Francis sold 1,000 shares of the business’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $60.46, for a total transaction of $60,460.00. Following the sale, the general counsel now directly owns 15,715 shares of the company’s stock, valued at $950,128.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul R. Lederer sold 2,200 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $60.87, for a total value of $133,914.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 160,403 shares of company stock valued at $9,912,181. Insiders own 3.10% of the company’s stock.
Several institutional investors have recently made changes to their positions in MMS. First Trust Advisors LP raised its position in shares of Maximus by 12.5% during the first quarter. First Trust Advisors LP now owns 25,806 shares of the health services provider’s stock worth $1,605,000 after purchasing an additional 2,865 shares during the period. World Asset Management Inc raised its position in shares of Maximus by 0.8% during the first quarter. World Asset Management Inc now owns 3,976 shares of the health services provider’s stock worth $247,000 after purchasing an additional 30 shares during the period. Karp Capital Management Corp acquired a new stake in shares of Maximus during the first quarter worth $1,078,000. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Maximus by 141.6% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 16,852 shares of the health services provider’s stock worth $1,048,000 after purchasing an additional 9,878 shares during the period. Finally, Stifel Financial Corp raised its position in shares of Maximus by 3.6% during the first quarter. Stifel Financial Corp now owns 8,731 shares of the health services provider’s stock worth $545,000 after purchasing an additional 302 shares during the period. 97.23% of the stock is currently owned by institutional investors.
Maximus (NYSE MMS) traded up 0.17% on Tuesday, reaching $65.70. The company’s stock had a trading volume of 49,005 shares. The firm has a 50-day moving average price of $62.23 and a 200 day moving average price of $61.79. Maximus has a 52-week low of $43.69 and a 52-week high of $65.87. The firm has a market capitalization of $4.26 billion, a P/E ratio of 21.06 and a beta of 1.36.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.